What it's for (Indications)
- Polygeline, a modified fluid gelatin preparation, is primarily indicated for the immediate and temporary restoration of circulating blood volume in conditions associated with hypovolemia or impending hypovolemic shock.
- This includes scenarios such as acute blood loss from trauma, surgery, or gastrointestinal hemorrhage, as well as significant fluid losses due to severe burns, septic shock, or other critical medical conditions.
- It is also utilized for plasma volume expansion during various medical procedures, including the prevention of hypotension during spinal or epidural anesthesia, and as a priming solution for extracorporeal circulation circuits in cardiopulmonary bypass or hemodialysis.
- Furthermore, polygeline may be employed for therapeutic hemodilution to improve microcirculation.
- Its role is crucial in stabilizing hemodynamics while definitive treatment for the underlying cause of hypovolemia is being initiated.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage and infusion rate of polygeline must be carefully individualized based on the patient's clinical condition, the extent of blood or fluid loss, hemodynamic parameters, and response to treatment. For acute hypovolemic shock, initial administration may involve rapid infusion of 500 to 1000 mL (one to two bottles) over 10-30 minutes, or even faster in life-threatening situations, under continuous monitoring of vital signs. Subsequent doses are adjusted to maintain adequate circulating volume and tissue perfusion. In less critical circumstances or for prophylactic volume expansion, infusion rates are typically slower, such as 250-500 mL over 30-60 minutes. Pediatric dosages should be determined based on body weight (e.g., 10-20 mL/kg, adjusted as needed) and the specific clinical indication. The maximum daily dose is not rigidly defined but should be guided by the patient's fluid balance, electrolyte status, and coagulation parameters to prevent circulatory overload or dilutional coagulopathy. Close monitoring of central venous pressure, blood pressure, heart rate, urine output, and hematocrit is essential throughout administration. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, polygeline can induce several side effects, primarily related to hypersensitivity reactions and fluid overload.
- The most common adverse events are mild to moderate anaphylactoid reactions, which are largely attributable to histamine release.
- These may manifest as skin reactions such as urticaria, pruritus, erythema, and flushing, alongside transient fever, chills, nausea, vomiting, or headache.
- More severe, though less frequent, reactions include bronchospasm, dyspnea, hypotension, tachycardia, angioedema, and, in rare instances, anaphylactic shock.
- Patients with a history of allergic reactions or asthma may be at an increased risk.
- Other potential side effects include circulatory overload, particularly in patients with pre-existing cardiac or renal impairment, leading to symptoms like dyspnea, elevated central venous pressure, or pulmonary edema.
- Although polygeline is designed to minimize effects on coagulation, very large volumes can rarely lead to dilutional coagulopathy.
- Minor electrolyte disturbances such as hypernatremia may also occur due to the preparation's sodium content.
Serious Warnings
- Black Box Warning: While polygeline, a plasma volume expander, does not carry a formal FDA-mandated Black Box Warning due to its primary usage outside the United States market and varying regulatory classifications, clinicians must be acutely aware of significant and potentially life-threatening risks associated with its administration. A paramount concern is the potential for severe anaphylactoid reactions, including anaphylactic shock, which can occur even with initial doses. These reactions are often histamine-mediated and can manifest as profound hypotension, bronchospasm, urticaria, angioedema, and cardiac arrest. Immediate access to emergency resuscitation equipment, including vasopressors, antihistamines, and corticosteroids, is critical during administration. Patients with a history of allergies, asthma, or known sensitivity to gelatin-derived products are at heightened risk. Furthermore, rapid or excessive infusion can precipitate severe circulatory overload, particularly in vulnerable patient populations such as those with pre-existing cardiac or renal dysfunction. This can lead to serious complications including pulmonary edema, acute congestive heart failure, and cerebral edema. Close monitoring of hemodynamic parameters, fluid balance, urine output, and respiratory status is essential throughout and following polygeline infusion to prevent and promptly manage these severe adverse events. The decision to use polygeline should always weigh its benefits for urgent volume replacement against these serious inherent risks.
- Polygeline is contraindicated in patients with known hypersensitivity to gelatin preparations or any component of the formulation.
- It should not be administered to individuals with severe congestive heart failure, pulmonary edema, severe renal insufficiency with oligo-anuria, or existing hypervolemia, as these conditions significantly increase the risk of fluid overload and exacerbation of underlying disease.
- Caution is advised in patients with a history of allergic conditions, asthma, or those receiving medications that might exacerbate histamine release, as they are at a higher risk of developing anaphylactoid reactions.
- Close monitoring is imperative for patients with impaired renal or cardiac function, as well as those with bleeding disorders, because large volumes may further compromise these systems or lead to dilutional coagulopathy.
- Electrolyte disturbances, particularly hypernatremia, should be monitored.
- Polygeline is not a substitute for blood or plasma products when oxygen-carrying capacity or coagulation factors are required.
- Patients should be observed for signs of anaphylaxis during and after infusion, and appropriate resuscitation measures must be readily available.
How it Works (Mechanism of Action)
Polygeline functions as a synthetic plasma volume expander, belonging to the class of modified fluid gelatins. Its mechanism of action primarily involves increasing the circulating blood volume through its oncotic properties. Comprising polypeptides with an average molecular weight of approximately 35,000 Daltons, polygeline molecules are sufficiently large to remain within the intravascular compartment for a significant period. Upon intravenous infusion, these molecules exert an osmotic effect, drawing extravascular fluid into the bloodstream, thereby expanding the plasma volume and enhancing cardiac output and tissue perfusion. The sustained presence of these macromolecules within the vasculature helps to maintain this volume expansion for several hours, typically 3-6 hours, depending on the dose and individual patient factors. Unlike blood, polygeline does not possess oxygen-carrying capacity or coagulation factors. It is primarily eliminated via renal excretion, with a relatively short half-life, making it a temporary solution for hypovolemia while the underlying cause is addressed. This colloidal property ensures that the expansion effect is largely confined to the vascular space, distinguishing it from crystalloid solutions.
Commercial Brands (Alternatives)
No other brands found for this formula.